Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eNOS-transfected autologous endothelial progenitor cells
- Development stage
- Phase 2
- Lead developer
- Northern Therapeutics
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intra-arterial
01
Overview
**eNOS-transfected autologous endothelial progenitor cells** is an investigational ex vivo gene-enhanced autologous cell therapy developed for vascular repair after acute myocardial infarction. Peripheral-blood-derived early endothelial progenitor cells are collected from the patient by apheresis, cultured and transfected to overexpress human endothelial nitric oxide synthase. The modified cells are subsequently administered into the infarct-related coronary artery. Increased endothelial nitric oxide synthase expression is intended to restore or augment nitric oxide-mediated endothelial repair, angiogenesis, cell survival, migration, and vascular regeneration in ischemic myocardium. The product was evaluated in the Phase IIb ENACT-AMI trial in patients with anterior ST-elevation myocardial infarction following coronary revascularization.
- Other names
- Autologous EPCs transfected with human eNOSeNOS-enhanced endothelial progenitor cellseNOS-transfected EPCs
02
Targets
NOS3 (eNOS)
Beyond the preview
Go deeper on eNOS-transfected autologous endothelial progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eNOS-transfected autologous endothelial progenitor cells.